Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients.
The efficacy of inhaled amphotericin B in prevention of invasive aspergillosis in patients with granulocytopenia (granulocytes less than 0.5 X 10(9)/l for greater than 10 days) was investigated over a 12-month period. Amphotericin B prophylaxis was administered twice daily for the period of granulocytopenia to 34 patients who were at risk during 144 episodes of granulocytopenia. The cohort at risk was compared with historical controls. In the 2 years prior to institution of prophylaxis, 14 patients (11.4% of those at risk) developed invasive aspergillosis. All cases occurred whilst the patients were nursed on the open wards. Aspergillosis did not develop in 25 granulocytopenic patients nursed in single rooms with HEPA filtration. Since institution of prophylaxis, there have been no cases of invasive aspergillosis. These data suggest that nebulized amphotericin B may be useful in preventing invasive pulmonary aspergillosis in granulocytopenic patients, especially those nursed on the open wards, and warrants further investigation.
Conneally
E
E
Department of Haematology, St. James Hospital, Dublin, Ireland.
Cafferkey
M T
MT
Daly
P A
PA
Keane
C T
CT
McCann
S R
SR
D000380:Agranulocytosis / Q000150:complications* / Q000453:epidemiology / Q000473:pathology; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000473:pathology; D006801:Humans; D008168:Lung / Q000382:microbiology / Q000473:pathology; D009330:Nebulizers and Vaporizers; D012307:Risk Factors
D000666:Amphotericin B